STAT+: Roivant autoimmune drug succeeds in Phase 2 study in eye condition

A drug being developed by a Roivant subsidiary for a range of autoimmune conditions succeeded in a mid-stage trial in an eye disease that can ultimately lead to blindness, Roivant said Tuesday.

The drug, brepocitinib, is being steered by a company called Priovant Therapeutics, which was formed as part of a deal between Roivant and Pfizer in 2021. 

The Phase 2 study tested different doses the oral drug in a disease called non-infectious uveitis, or NIU, which causes inflammation in the eye that can result in blindness. The primary endpoint of the trial, which was not placebo-controlled, was treatment failure at 24 weeks, with a lower treatment failure signifying a greater treatment benefit. The study included 26 participants.

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Roivant autoimmune drug succeeds in Phase 2 study in eye condition »